选择语言

Biotinylated Human HVEM / TNFRSF14 Protein, Fc,Avitag™ (MALS verified)

用户评价
货号-规格
价格
Qty.
HVM-H82F6-25ug
¥3675.00
HVM-H82F6-200ug
¥14490.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    TNFRSF14,ATAR,HVEA,HVEM,LIGHTR,TR2,CD270

  • 表达区间及表达系统(Source)

    Biotinylated Human HVEM, Fc,Avitag (HVM-H82F6) is expressed from human 293 cells (HEK293). It contains AA Leu 39 - Val 202 (Accession # Q92956-1).

    Predicted N-terminus: Leu 39

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    HVEM Structure

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 45.5 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 偶联(Conjugate)

    Biotin

  • 标记(Labeling)

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method.

  • 纯度(Purity)

    95% as determined by SDS-PAGE.

    90% as determined by SEC-MALS.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • 电泳(SDS-PAGE)

    HVEM SDS-PAGE

    Biotinylated Human HVEM, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    HVEM SEC-MALS

    The purity of Biotinylated Human HVEM, Fc,Avitag (Cat. No. HVM-H82F6) is more than 90% and the molecular weight of this protein is around 100-120 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     HVEM ELISA

    Immobilized Human LIGHT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. LIT-H5256) at 2 μg/mL (100 μL/well) can bind Biotinylated Human HVEM, Fc,Avitag (Cat. No. HVM-H82F6) with a linear range of 0.6-39 ng/mL (QC tested).

    Protocol
  •  HVEM ELISA

    Immobilized Biotinylated Human HVEM, Fc,Avitag (Cat. No. HVM-H82F6) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human CD160 Protein, His Tag with a linear range of 1-78 ng/mL (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

Herpesvirus entry mediator (HVEM) is also known as TNFRSF14, TR2 (TNF receptorlike molecule) and ATAR (another TRAF associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D (gD). Two TNF superfamily ligands, including the secreted TNFβ (lymphotoxin α) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LTβR, the receptor for lymphotoxin αβ heterotrimer. The role of the HVEM LIGHT /LTβ receptor ligand pair in immune function and herpesvirus pathobiology remains to be elucidated.

前沿进展

 
药物研发进展
  • 英文全称:

    Tumor necrosis factor receptor superfamily member 14

  • 中文全称:

    肿瘤坏死因子受体超家族成员14

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    0 详情

  • 最高研发阶段:

    临床前

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍